Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy
Authors Li X, Jia X, Niu H
Received 28 January 2018
Accepted for publication 5 March 2018
Published 12 July 2018 Volume 2018:13 Pages 4107—4119
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Linlin Sun
Xin Li,1 Xiaoqian Jia,2 Hu Niu2
1Department of Breast and Thyroid Surgery, Heze Municipal Hospital, Heze, Shandong, China; 2Department of General Surgery 2, The Fourth People’s Hospital of Jinan, Jinan, Shandong, China
Background: Multidrug resistance is responsible for the poor outcome in breast cancer therapy. Lapa is a novel therapeutic agent that generates ROS through the catalysis of the NAD(P)H:quinone oxidoreductase-1 (NQO1) enzyme which significantly facilitate the intracellular accumulation of the co-delivered DOX to overcome MDR in cancer cells.
Purpose: Herein, in our study, nanostructured lipid carrier (NLC) co-delivering β-lapachone (Lapa) and doxorubicin (DOX) was developed (LDNLC) with the aim to overcome the multidrug resistance (MDR) in breast cancer therapy.
Patients and methods: Lapa and DOX were loaded into NLC to prepare LDNLC using melted ultrasonic dispersion method.
Results: The well designed LDNLC was nanoscaled particles that exhibited preferable stability in physiological environment. In vitro cell experiments on MCF-7 ADR cells showed increased DOX retention as compared to DOX mono-delivery NLC (DNLC). In vivo anti-cancer assays on MCF-7 ADR tumor bearing mice model also revealed significantly enhanced efficacy of LDNLC than mono-delivery NLCs (DNLC and LNLC).
Conclusion: LDNLC might be a promising platform for effective breast cancer therapy.
Keywords: β-lapachone, doxorubicin, nanostructured lipid carriers, multidrug resistance, breast cancer
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]